- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Marianne Nicolson
Consultant Medical Oncologist, Aberdeen Royal Infirmary, Aberdeen, Scotland
If we look at the delivery of the current anti-angiogenic drugs, some of them are given by intravenous injection, and even if that’s only three weeks, it still does mean that the patient has to come up to the hospital or go to the nurse at a clinic to have that needle put in and have the treatment delivered. The newer drugs coming through are given by mouth – and that is much easier for the patient, in terms of their compliance and in terms of their ability to keep running their own lives and not to be tied to hospitals at frequent intervals, it’s much better for the patient.
The other thing is that some of the drugs work better with chemotherapy than others. And therefore if giving one of these new oral drugs in combination with chemotherapy gives more than additive effect where two and two gives you six instead of just four, then we really do think that we are making progress in treating lung cancer.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
